#China #LabConnect #Clinical Trials #Wuxi #Wuxi Facility

LabConnect Expands Global Central Laboratory Infrastructure

LabConnect, a prominent provider of technology-driven central laboratory services, has made a significant leap in its offerings by inaugurating a new facility in Wuxi, China. This strategic move comes as the clinical trial landscape grows more intricate, with sponsors increasingly on the lookout for well-integrated partners capable of providing comprehensive testing services, logistics, and data management.

The Wuxi facility is designed to strengthen LabConnect's commitment to supporting multi-regional clinical trials. With existing capabilities already established in Australia, the new site positions LabConnect to better assist Asia-Pacific pharmaceutical and biotechnology organizations expand their research endeavors internationally. As stated by Wes Wheeler, the CEO of LabConnect, “This facility reflects LabConnect's continued investment in building the global services needed to support clinical trials today and the next generation of clinical research.”

Fully integrated into LabConnect's worldwide infrastructure, this new facility empowers study teams to operate across different regions with a unified data system. This integration promises consistency in operational oversight and efficient sample handling and logistics.

Developed in collaboration with Teddy Laboratory, which is now part of Frontage Laboratories, the facility combines local expertise with LabConnect's extensive global services. It supports a wide array of clinical trial services, including custom kit assembly, advanced sample tracking, and biorepository services, all tailored to comply with international regulatory standards.

At the grand opening event held in Wuxi’s Xinwu District, the attendees engaged in a ceremonial ribbon-cutting, followed by guided laboratory tours showcasing LabConnect's innovative approach to central laboratory services. The event was marked by presentations that highlighted the capabilities of the Wuxi facility, which plays a critical role in supporting both multinational pharmaceutical companies entering the Chinese market and local companies seeking to expand internationally.

With the opening of the Wuxi facility, LabConnect now operates in eight global locations, making it easier for sponsors and Contract Research Organizations (CROs) to rely on a single partner for comprehensive laboratory services. This consolidation simplifies the complexities of managing clinical trials that span multiple geographies.

LabConnect stands out for its unique decentralized laboratory network model that connects various laboratories, logistics, technology, and scientific expertise, allowing for the effective delivery of integrated solutions for clinical trials worldwide. This approach not only boosts operational efficiency but also enhances the safety and reliability of clinical trial outcomes.

For more information about LabConnect and its global laboratory services, visit LabConnect’s official website. By fostering innovation and expanding its global reach, LabConnect is setting a benchmark in the clinical trial sector, ensuring that research organizations have the robust support they need to navigate the evolving landscape of clinical research.